Drugs & Therapy Perspectives

, Volume 5, Issue 1, pp 5–7 | Cite as

Azapirones have potential in a wide variety of CNS disorders

New Drugs and Therapeutics


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pecknold JC. Serotonin 5-HT1A agonists. A comparative review. CNS Drugs 1994; 2: 234–51CrossRefGoogle Scholar
  2. 2.
    Heller AH, Beneke M, Kuemmel B. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 1990; 26: 219–22PubMedGoogle Scholar
  3. 3.
    Palmer KJ, Benfield P. Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994; 1: 57–87CrossRefGoogle Scholar
  4. 4.
    Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895–924PubMedCrossRefGoogle Scholar
  5. 5.
    Tiller J, Schweitzer I, Maguire K, et al. Is diazepam an antidepressant? Br J Psychiatry 1989; 155: 483–9PubMedCrossRefGoogle Scholar
  6. 6.
    Ashton H. Guidelines for the rational use of benzodiazepines. Drugs 1994; 48: 25–40PubMedCrossRefGoogle Scholar
  7. 7.
    Burrows GD, Judd FK, Norman TR. Differential diagnosis and drug treatment of panic disorder, anxiety and depression. CNS Drugs 1994; 1: 119–31CrossRefGoogle Scholar
  8. 8.
    Boyer WF, Feighner JP. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 1993; 8: 173–6PubMedCrossRefGoogle Scholar
  9. 9.
    Steinberg JR. Anxiety in elderly patients. A comparison of azapirones and benzodiazepines. Drugs Aging 1994; 5: 335–45PubMedCrossRefGoogle Scholar
  10. 10.
    Cutler NR, Sramek JJ, Wardle TS. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalised anxiety disorder: single site findings from a multicenter trial. Psycopharmacol Bull 1993; 29: 303–8Google Scholar
  11. 11.
    Murasaki M, Mori A, Kudo Y. Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. A comparative double-blind study with diazepam. Neuropsychopharmacology 1993; 9 (2 Suppl.); 125Google Scholar
  12. 12.
    Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990; 83: 194–8PubMedCrossRefGoogle Scholar
  13. 13.
    Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48 (12 Suppl.): 3–6PubMedGoogle Scholar
  14. 14.
    Robinson DS, Rickels K, Feighner J. Clinical effects of the 5-HT1A partial agonists in the treatment of depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 (3 Suppl.): 67–76CrossRefGoogle Scholar
  15. 15.
    Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217–20PubMedGoogle Scholar
  16. 16.
    Pecknold JC, Luthe L, Scott-Fleury M-H, et al. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 1993; 13: 145–9PubMedCrossRefGoogle Scholar
  17. 17.
    Inhibition of serotonin reuptake is the key to treating obsessive-compulsive disorder. Drug Ther Perspect 1993 Aug 30; 2(4): 8–10Google Scholar
  18. 18.
    Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127–9PubMedGoogle Scholar
  19. 19.
    1994 Physicians GenRx. New York: Data Pharmaceutica Inc., 1994; 297–9Google Scholar
  20. 20.
    British National Formulary 1994; 27: 143Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations